Franziska Bannwart

Ms. Franziska Bannwart


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FBFranziska Bannwart
Franziska Bannwart
LRLeon F. Richter
Leon F. Richter
SSSimon Stifel
Simon Stifel
JRJohanna Rueter
Johanna Rueter
HLHolger N. Lode
Holger N. Lode
APAram Prof. Dr. Dr. Prokop
Aram Prof. Dr. Dr. Prokop
From previous studies, it is evident that metal-organic gold(I) complexes have antiproliferative activities. The aim of this study is not only to find new anticancer agents but also to overcome existing cytostatic resistance in cancer cells. The synthesis and medicinal evaluation of two cationic 1,3-disubstituted gold(I) bis-tetrazolylidene complexes 1 and 2 are reported. To determine apoptosis-inducing properties of the complexes, DNA fragmentation was measured using propidium iodide staining followed by flow cytometry. Gold(I) complex 1 targets explicitly malignant cells, effectively inhibiting their growth and selectively inducing apoptosis without signs of necrosis. Even in cells resistant to common treatments such as doxorubicin, it overcomes multidrug resistance and sensitizes existing drug-resistant cells to common cytostatic drugs. It is assumed that gold(I) complex 1 involves the mitochondrial pathway in apoptosis and targets members of the BCL-2 family, enhancing its potential as a therapeutic agent in cancer treatment.

27 October 2026 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
JRJohanna Rueter
Johanna Rueter
FBFranziska Bannwart
Franziska Bannwart
SBSebastian Bieringer
Sebastian Bieringer
JWJennifer Witt
Jennifer Witt
JFJerico Frias
Jerico Frias
APAram Prokop
Aram Prokop